Roche's MAJESTY Study Delivers Positive Phase III Data for Gazyva in Membranous Nephropathy
Roche announced that the Phase III MAJESTY study evaluating Gazyva/Gazyvaro (obinutuzumab) in primary membranous nephropathy met its primary endpoint, with more patients achieving complete remission at two years compared to tacrolimus. Obinutuzumab is a glycoengineered, type II anti-CD20 monoclonal antibody designed to achieve deep tissue B cell depletion, and it is already approved in the US and EU for the treatment of lupus nephritis and several haematological cancers. If regulators grant approval for this new indication, Gazyva would become the first therapy specifically indicated for primary membranous nephropathy treatment — a disease that currently lacks any approved drug and where off-label regimens remain the standard of care.
Trial Specifics: The Roche MAJESTY Study and Obinutuzumab Phase III Results
MAJESTY is a Phase III, randomised, open-label, multicentre trial that enrolled 142 adults with primary membranous nephropathy. Participants were randomised 1:1 to receive either obinutuzumab or tacrolimus, a calcineurin inhibitor that is among the immunosuppressive agents used off-label in this setting. The primary endpoint was the percentage of patients achieving membranous nephropathy complete remission at 104 weeks. The company reported that the obinutuzumab arm achieved a statistically significant and clinically meaningful advantage over tacrolimus on this measure, though exact response rates, confidence intervals, and p-values were not disclosed in the topline announcement. Analysis of key secondary endpoints also favoured obinutuzumab, with statistically significant differences observed in overall remission (complete or partial) at week 104 and in complete remission at week 76, suggesting both earlier onset and sustained benefit. Safety was consistent with the established profile of Gazyva/Gazyvaro across its approved indications, and no new safety signals were identified. The press release did not provide detailed adverse event rates, infusion reaction incidence, or discontinuation data.
Roche stated that full data from the MAJESTY study will be presented at an upcoming medical meeting and shared with the US FDA and the European Medicines Agency. Levi Garraway, Roche's Chief Medical Officer and Head of Global Product Development, said the results "demonstrate that Gazyva/Gazyvaro may help more people with primary membranous nephropathy achieve complete remission, maintain kidney function for longer and delay or potentially prevent the onset of life-threatening complications." The company did not specify a timeline for regulatory submissions, though the language used — referencing plans to share data with health authorities — indicates that filings are being prepared. MAJESTY is the fourth positive Phase III study for obinutuzumab in immune-mediated diseases, following REGENCY in lupus nephritis, ALLEGORY in systemic lupus erythematosus, and INShore in idiopathic nephrotic syndrome.
Mechanism and Disease Context: Why Gazyva Gazyvaro Matters in Autoimmune Disease
Primary membranous nephropathy is a chronic autoimmune condition in which antibodies — most commonly directed against the phospholipase A2 receptor (PLA2R) on kidney podocytes — cause immune complex deposition in the glomerular basement membrane, leading to proteinuria and progressive kidney damage. Roche estimates that the disease affects nearly 88,000 people in the EU and over 96,000 in the US. Up to 30% of patients progress to kidney failure over a decade, at which point dialysis or transplantation becomes necessary.
The rationale for targeting CD20 in this disease rests on the understanding that autoreactive B cells are the upstream source of the pathogenic autoantibodies. By depleting CD20-positive B cells, obinutuzumab aims to eliminate the cellular machinery sustaining autoantibody production. Obinutuzumab is distinguished from earlier anti-CD20 antibodies by two structural features: a type II anti-CD20 binding domain that induces direct B cell death more effectively, and a glycoengineered Fc region that enhances antibody-dependent cellular cytotoxicity. Together, these properties are designed to produce deeper and more durable B cell depletion than type I anti-CD20 agents such as rituximab. Case series in rituximab-refractory membranous nephropathy have documented that obinutuzumab can achieve immunologic remission — measured by declines in anti-PLA2R antibody titres — followed by reductions in proteinuria, consistent with the expected causal chain from antibody suppression to clinical improvement.
Obinutuzumab is approved in the US and EU for adults with active lupus nephritis, based on data from the REGENCY and NOBILITY studies. It is also approved in over 100 countries for chronic lymphocytic leukaemia and follicular lymphoma. In the oncology setting, it has received US FDA Breakthrough Therapy Designation, Priority Review, Orphan Drug Designation, and Fast Track Designation for CLL. No such designations have been reported for any nephrology indication. The molecule originated at GlycArt Biotechnology, a Swiss biotech company whose glycoengineering platform was acquired by Roche in 2005, and it has remained wholly within the Roche portfolio since.
Competitive Landscape: Anti-CD20 Therapies in Primary Membranous Nephropathy
The competitive context for obinutuzumab in membranous nephropathy is defined almost entirely by rituximab, which has become the de facto standard of care despite lacking formal approval for this indication in most jurisdictions. The 2021 KDIGO guidelines recommend rituximab as a first-line option for primary membranous nephropathy, and several Phase III trials have established its efficacy profile. No other anti-CD20 agent has advanced beyond case series or early-phase investigation in this disease. Key competitors and relevant agents include: